Clinical Significance of Expression of CDKN1C in Bone Marrow in Patients with Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia
10.3969/j.issn.1671-7414.2017.05.010
- VernacularTitle:骨髓中CDKN1C的表达在骨髓增生异常综合征和继发性急性髓系白血病患者中检测的临床意义
- Author:
ying Xiao FU
1
;
Guang LI
;
li Yan JIN
Author Information
1. 宝鸡市中心医院血液科
- Keywords:
CDKN1C;
myelodysplastic syndrome;
secondary acute myeloid leukemia;
bone marrow
- From:
Journal of Modern Laboratory Medicine
2017;32(5):36-40
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of CDKN1C in bone marrow in myelodysplastic syndromes and clinical significance of the detection of syndrome and secondary acute myeloid leukemia patients.Methods 125 patients with MDS/ AML were selected as the research object,and selected 20 cases of healthy people as healthy control group,and to investigate the mRNA and protein expression in CD34+ cells in bone marrow the expression of MDS/AML in patients and the survival rate of different expression of CDKN1C,to analyze the factors for survival rate of patients with MDS by Cox regression,and analyze the different treatment methods in patients with MDS/AML.Results The expression lcvcls of CDKN1C mRNA and protein of bone marrow CD34 + cells in the patients with MDS/AML were significantly higher than the healthy control group (t=5.324,7.326;P=0.002,0.000),and which was positive with BM count (r=2.014,P=0.004);the survival rate of CDKN1C high expression levels in patients with MDS/AML was significantly lower than that of the low expression of CDKN1C group and intermediate CDKN1C expression group (P＜0.05).Cox regression analysis showed that age,high BM count,cytogenetic risk difference and CDKN1C positive significantly affect the survival rate of patients with MDS/AML (95％CI=1.10～1.32,1.92～4.40,1.18～2.67,1.03～2.32,P=0.034～0.000).MDS/AML chemotherapy in CDKN1C positive group was significantly lower than the survival rate of patients with CDKN1C negative expression group (t=5.314,P=0.002).Conclusion The expression of CDKN1C in bone marrow of patients with MDS/AML was significantly increased,and the high expression of CDKN1CMDS/AML effect of chemotherapy on the survival rate of patients with MDS/AML.
